Cytonics has developed a novel biologic solution for osteoarthritis, the debilitating joint disease which affects over 30M Americans1 and 600M people worldwide2. Now is the opportunity to invest in our first-in-class biopharmaceutical as we prepare for Phase 1 human clinical trials.
